Castration-resistant Prostate Cancer Treatment Market

Request Discount

Castration-resistant Prostate Cancer Treatment Market (Therapy Type - Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy; Drug Delivery Method - Oral Therapy, and Injectable Therapy; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2027

  • Published : February, 2022

  • Rep Id : HC08738

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the castration-resistant prostate cancer treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional castration-resistant prostate cancer treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional castration-resistant prostate cancer treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global castration-resistant prostate cancer treatment market. According to the report, the global castration-resistant prostate cancer treatment market is projected to grow at a CAGR of 8.5% around the forecast period of 2021-2027, growing from nearly USD 9 billion in 2021 to around USD 15 billion in 2027.

Market Insight

Castrate-resistant prostate cancer is prostate cancer that stops responding to hormone therapy. Hormone therapy, also known as androgen deprivation therapy (ADT), lowers testosterone levels in the body. Most prostate cancer these days are diagnosed at an early stage when the cancer is still confined to the prostate gland. In the case of Men, they have to undergo surgery to remove the cancerous prostate gland or radiation treatment to destroy the cancerous cells in the gland. Male sex hormones fuel prostate cancer. The main hormone that is been driven by prostate cancer is testosterone, which is produced in the testicles. A combination of drugs and other types of treatments can lower the progression of castrate-resistant prostate cancer, even if it has metastasized. Two relatively new hormone therapies have relatively shown promising results for castrate-resistant and metastatic prostate cancer such as chemotherapy, Abiraterone, and Enzalutamide.


The increasing number of prostate cancer patients, increasing research and development activities in highly developed countries, and increasing product launches by the major market players are some of the driving factors, which are expected to drive the growth of the market. Moreover, the increasing number of clinical trials for the treatment of castrate-resistant prostate cancer is expected to boost the global castrate-resistant prostate cancer market over the forecasting years. Lack of awareness amongst the people about the treatments and lack of proper healthcare facilities present in a few developing countries will restrain the market growth. The growing awareness regarding the treatment in highly developed countries and the surging geriatric population have created lucrative growth opportunities for the players to grow.


Among the regions, North America accounted for the largest share in the global Castration-Resistant Prostate Cancer Treatment Market. Due to the high prevalence of the disease, the presence of major market players, and moreover the increasing research and development activities, and favorable reimbursement policies in this region will propel the market condition in the upcoming future also. However, the Asia Pacific region is anticipated to grow with the highest rate in the global Castration-Resistant Prostate Cancer Treatment over the forecast period. The extensive increase in the healthcare infrastructure and presence of leading oncology companies and increase in R&D investments in countries such as China and Japan will propel its market growth in the upcoming years


Castration-resistant Prostate Cancer Treatment Market

Segment Covered

The report on the global castration-resistant prostate cancer treatment market covers segments such as therapy type, drug delivery method, and distribution channel. On the basis of therapy type, the sub-markets include chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. On the basis of drug delivery method, the sub-markets include oral therapy, and injectable therapy. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.


Companies Profiled:

The report provides profiles of the companies in the market such as Pfizer Inc., Astellas Inc, Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc, Active Biotech AB, Dendreon Pharmaceuticals LLC, and Pfizer Inc..


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the castration-resistant prostate cancer treatment market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount